المؤلفون: R. Kazakov Ye., O. Checha A., I. Mazerkina A., E. Demchenkova Yu., T. Aleksandrova A., V. Evteev A., S. Belkov A., A. Prokofiev B., Р. Казаков Е., О. Чеча А., О. Муслимова В., Е. Демченкова Ю., Т. Александрова В., В. Евтеев А., С. Белков А., А. Прокофьев Б.

المساهمون: The study reported in this publication was carried out as part of a publicly funded research project No. 056-00003-20-00 and was supported by the Scientifi c Centre for Expert Evaluation of Medicinal Products (R&D public accounting No. AAAA-A18-118021590047-6)., Работа выполнена в рамках государственного задания ФГБУ «НЦЭСМП» Минздрава России № 056-00003-20-00 на проведение прикладных научных исследований (номер государственного учета НИР AAAA-A18-118021590047-6)

المصدر: Safety and Risk of Pharmacotherapy; Том 8, № 1 (2020); 43-51 ; Безопасность и риск фармакотерапии; Том 8, № 1 (2020); 43-51 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2020-8-1

مصطلحات موضوعية: pharmacogenetics, genotyping, genetic biomarkers, statins, atorvastatin, single nucleotide polymorphisms, P-glycoprotein, organic anion transporters, SLCO1B1, ABCB1, CYP2C9, CYP2C19, фармакогенетика, генотипирование, генетические биомаркеры, статины, аторвастатин, однонуклеотидные полиморфизмы, Р-гликопротеин, транспортеры органических анионов

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/160/233; Чазов ЕИ. Пути снижения смертности от сердечно-сосудистых заболеваний. Терапевтический архив. 2008;80(8):11–6.; Ощепкова ЕВ, Ефремова ЮЕ, Карпов ЮА. Заболеваемость и смертность от инфаркта миокарда в Российской Федерации в 2000–2011 гг. Терапевтический архив. 2013;85(4):4–10.; Смирнова МД, Агеев ФТ. Статины — старые мифы и новые факты. РМЖ. 2017;(20):1421–8.; Сухатерина НА. Динамика показателей липидного спектра и маркеров воспаления на фоне приема атор вастатина у пациентов с артериальной гипертензией в сочетании с хронической обструктивной болезнью легких. Атеросклероз и дислипидемии. 2016;(3):68–74.; Недогода СВ. Розувастатин: доказательная база и значение для реальной клинической практики. РМЖ. 2015;(15):886.; Кухарчук ВВ, Семенова АЕ. Коррекция гиперлипидемии: особенности терапии статинами на примере пострегистрационного исследования «КОМПЛАЕНС». Атеросклероз и дислипидемии. 2015;(1):5–11.; Ежов МВ, Близнюк СА, Алексеева ИА, Выгодин ВА. Распространенность гиперхолестеринемии и применения статинов в амбулаторной практике в Российской Федерации. Исследование АЙСБЕРГ — диагностирование пациентов с гиперхолестеринемией в условиях амбулаторной практики на раннем этапе с целью улучшения сердечно-сосудистого прогноза. Атеросклероз и дислипидемии. 2017;(4):5–17.; Барбараш ОЛ, Кашталап ВВ, Шибанова ИА. Пациент после эпизода острого коронарного синдрома. Контроль липидов после острого коронарного синдрома. Атеросклероз и дислипидемии. 2019;10(2):5–14.; Драпкина ОМ. Применение статинов при остром коронарном синдроме. Кардиоваскулярная терапия и профилактика. 2009;8(5):69–73.; Franssen R, Vergeer M, Stroes ES, Kastelein JJ. Combination statin–fi brate therapy: safety aspects. Diabetes Obes Metab. 2009;11(2):89–94. https://doi.org/10.1111/j.1463-1326.2008.00917.x; Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Eff ect of statins on skeletal muscle function. Circulation. 2013;127(1):96–103. https://doi.org/10.1161/CIRCULATIONAHA.112.136101; Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association’s Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S47–57. https://doi.org/10.1016/j.jacl.2014.02.011; Горошко ОА, Красных ЛМ, Кукес ВГ, Зозина ВИ. Значение редокс-статуса коэнзима Q10 как биомаркера окислительного стресса. Ведомости Научного центра экспертизы средств медицинского применения. 2019;9(3):146–52.; Hoenig MR, Walker PJ, Gurnsey C, Beadle K, Johnson L. The C3435T polymorphism in ABCB1 infl uences atorvastatin effi cacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol. 2011;5(2):91–6. https://doi.org/10.1016/j.jacl.2011.01.001; Ramakumari N, Indumathi B, Katkam SK, Kutala VK. Impact of pharmacogenenetics on statin-induced myopathy in South-Indian sudjects. Indian Heart J. 2018;70(Suppl 3):S120–5. https://doi.org/10.1016/j.ihj.2018.07.009; Talameh JA, Kitzmiller JP. Pharmacogenetics of statin-induced myopathy: a focused review of the clinical translation of pharmacokinetic genetic variants. J Pharmacogenomics Pharmacoproteomics. 2014;5(2):128. https://doi.org/10.4172/2153-0645.1000128; Buzková H, Pechandová K, Danzig V, Vařeka T, Perlík F, Žák A, Slanař O. Lipid-lowering eff ect of fl uvastatin in relation to cytochrome P450 2C9 variant alleles frequently distributed in the Czech population. Med Sci Monit. 2012;18(8):CR512–7. https://doi.org/10.12659/msm.883272; Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid-modifying effi cacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol. 2012;109(9):1239–46. https://doi.org/10.1016/j.amjcard.2011.12.015; SEARCH Collaborative Group, Link E, Parish S, Armit age J, Bowman L, Heath S, et al. SLCO1B1 variants and statininduced myopathy — a genomewide study. N Engl J Med. 2008;359(8):789–99. https://doi.org/10.1056/NEJMoa0801936; https://www.risksafety.ru/jour/article/view/160

الاتاحة: https://www.risksafety.ru/jour/article/view/160
https://doi.org/10.30895/2312-7821-2020-8-1-43-51

المؤلفون: V. Evteev A., R. Kazakov E., O. Muslimova A., E. Demchenkova Yu., В. Евтеев А., Р. Казаков Е., О. Муслимова А., Е. Демченкова Ю.

المصدر: Safety and Risk of Pharmacotherapy; Том 6, № 2 (2018); 78-85 ; Безопасность и риск фармакотерапии; Том 6, № 2 (2018); 78-85 ; 2619-1164 ; 2312-7821 ; 10.30895/2312-7821-2018-6-2

مصطلحات موضوعية: Transporters, organic cations, pharmacogenetics, SNP, SLC, SLC22A, OCT1, OCT2, OCT3, транспортеры, органические катионы, фармакогенетика, OСT1, OСT2, OСT3

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/104/105; Sanjay K. Nigam. What do drug transporters really do? Nat Rev Drug Discov. 2015 Jan; 14(1): 29–44.; Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007 Jul; 24 (7): 1227–51.; Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol. 2012 Mar; 165(5): 1260–87.; Saborowski M, Kullak-Ublick GA, Eloranta JJ. The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha. J Pharmacol Exp Ther. 2006; 317: 778–85.; Shu Y, Bello CL, Mangravite LM, Feng B, Giacomini KM Functional characteristics and steroid hormone-mediated regulation of an organic cation transporter in Madin-Darby canine kidney cells. J Pharmacol Exp Ther. 2001. 299: 392–8.; Wu X, Huang W, Ganapathy ME, Wang H, Kekuda R, Conway SJ, Leibach FH, Ganapathy V. Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep; 279(3): F449–58.; Barendt WM, Wright SH. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J Biol Chem. 2002 Jun 21; 277(25): 22491–6.; Nies AT, Koepsell H, Damme K, Schwab M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb Exp Pharmacol. 2011; (201): 105–67.; Moaddel R, Ravichandran S, Bighi F, Yamaguchi R, Wainer IW. Pharmacophore modelling of stereoselective binding to the human organic cation transporter (hOCT1). Br J Pharmacol. 2007 Aug; 151(8): 1305–14.; Volk C, Gorboulev V, Kotzsch A, Müller TD, Koepsell H. Five amino acids in the innermost cavity of the substrate binding cleft of organic cation transporter 1 interact with extracellular and intracellular corticosterone. Mol Pharmacol. 2009 Aug; 76(2): 275–89.; Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, Baumann C, Lang F, Busch AE, Koepsell H. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul; 16(7): 871–81.; Zhang L, Dresser MJ, Chun JK, Babbitt PC, Giacomini KM. Cloning and functional characterization of a rat renal organic cation transporter isoform (rOCT1A). J Biol Chem. 1997 Jun 27; 272(26): 16548–54.; Hayer M, Bonisch H, Bruss M. Molecular cloning, functional characterization and genomic organization of four alternatively spliced isoforms of the human organic cation transporter 1 (hOCT1/SLC22A1). Ann Hum Genet. 1999; 63: 473–82.; Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Gorboulev V, Mornhinweg E, Keil A, Eichelbaum M, Koepsell H. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics. 2002 Nov; 12(8): 591–5.; Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variationin the organic cation transporter 1 (OCT1). J Clin Invest. 2007; 117: 1422–31.; Shu Y, Leabman MK, Feng B, Mangravite LM. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci USA. 2003; 100:5902–7.; Tzvetkov MV, Santos Pereira dos JN, Meineke I, Saadatmand AR, Stingl JC, BrockmÖller J. Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration. Biochem Pharmacol. 2013; 86: 666–78.; Fukuda T, Chidambaran V, Mizuno T, Venkatasubramanian R, Ngamprasertwong P, Olbrecht V, et al. OCT1 genetic variants influence the pharmacokinetics of morphine in children. N Pharmacogenomics. 2013; 14:1141–51.; Zolk O, Solbach TF, König J, Fromm MF. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab Dispos. 2009 Jun; 37(6): 1312–8.; Iwata K, Aizawa K, Kamitsu S, Jingami S, Fukunaga E, Yoshida M, Yoshimura M, Hamada A, Saito H. Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin Exp Nephrol. 2012 Dec; 16(6): 843–51.; Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002; 12: 395–405.; Fukushima-Uesaka H, Maekawa K, Ozawa S, Komamura K, Ueno K, Shibakawa M, Kamakura S, Kitakaze M, Tomoike H, Saito Y, et al. Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab Pharmacokinet. 2004; 19: 239–44.; Ogasawara K, Terada T, Motohashi H, Asaka J, Aoki M, Katsura T, Kamba T, Ogawa O, and Inui K Analysis of regulatory polymorphisms in organic ion transporter genes(SLC22A) in the kidney. J Hum Genet. 2008; 53: 607–14.; Sakata T, Anzai N, Kimura T, Miura D, Fukutomi T, Takeda M, Sakurai H, Endou H. Functional analysis of human organic cation transporter OCT3 (SLC22A3) polymorphisms. J Pharmacol Sci. 2010; 113(3): 263–6.; Chen L, Pawlikowski B, Schlessinger A, More SS, Stryke D, Johns SJ, Portman MA, Chen E, Ferrin TE, Sali A, Giacomini KM. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet Genomics. 2010 Nov; 20(11): 687–99.; Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther. 2004; 308: 2–9.; Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol. 1987 May; 23(5): 545–51.; Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther. 2011 Mar;10(3): 531–9.; Tanihara Y, Masuda S, Katsura T, Inui K. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2. Biochem Pharmacol. 2009 Nov 1; 78(9): 1263–71.; Somogyi A and Heinzow B. Cimetidine reduces procainamide elimination. N Engl J Med. 1982; 307: 1080.; Wang, Z.J., et al., OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet Genomics, 2008. 18 (7): Р. 637–45.; https://www.risksafety.ru/jour/article/view/104

الاتاحة: https://www.risksafety.ru/jour/article/view/104
https://doi.org/10.30895/2312-7821-2018-6-2-78-85

المؤلفون: V. Evteev A., O. Muslimova V., I. Mazerkina A., N. Bunyatyan D., E. Shikh V., R. Kazakov E., В. Евтеев А., О. Муслимова В., И. Мазеркина А., Н. Бунятян Д., Е. Ших В., Р. Казаков Е.

المصدر: Safety and Risk of Pharmacotherapy; Том 5, № 2 (2017); 70-75 ; Безопасность и риск фармакотерапии; Том 5, № 2 (2017); 70-75 ; 2619-1164 ; 2312-7821 ; undefined

مصطلحات موضوعية: транспортеры, β-лактамные антибиотики, SLC, OAT1, OAT3, OAT4, OATP1A2, OATP1B1, OATP1B3, transporters, β-lactam antibiotics

وصف الملف: application/pdf

Relation: https://www.risksafety.ru/jour/article/view/71/72; Nigam SK, Bush KT, Martovetsky G, Ahn S-Y, Liu HC, Richard E, et al. The Organic Anion Transporter (OAT) Family: A Systems Biology Perspective. Physiol Rev. 2015 Jan; 95 (1): 83-123.; Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm. Res. 2007; 24: 450-470.; Emami Riedmaier A, Nies AT, Schaeffeler E, Schwab M. Organic anion transporters and their implications in pharmacotherapy. Pharmacol Rev. 2012 Jul; 64(3): 421-49.; Rammelkamp CH, Keefer CS. The absorption, excretion, and distribution of penicillin. J Clin Invest. 1943 May; 22(3): 425-37.; Hagos Y, Natascha A. Wolff. Assessment of the Role of Renal Organic Anion Transporters in Drug-Induced Nephrotoxicity. Toxins 2010, 2, 2055-2082; doi:10.3390/toxins2082055; Brown GR. Cephalosporin-probenecid drug interactions. Clin. Pharmacokinet. 1993; 24: 289-300.; Takeda M, Khamdang S, Narikawa S, et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther. 2002; 302: 666-671.; Jaehde U, Sorgel F, Reiter A, et al. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. Clin. Pharmacol. Ther. 1995; 58: 532-541.; Takeda ML, Babu E, Narikawa S, Endou H. Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8; 438(3): 137-42.; Tune BM, Fravert D, Hsu CY. Thienamycin nephrotoxicity. Mitochondrial injury and oxidative effects of imipenem in the rabbit kidney. Biochem. Pharmacol. 1989; 38: 3779-3783.; Lim SC, Im YB, Bae CS, Han SI, Kim SE, Han HK. Protective effect of morin on the imipenem-induced nephrotoxicity in rabbits. Arch. Pharm. Res. 2008; 31: 1060-1065.; Enomoto AL, Takeda M, Shimoda M, Narikawa S, Kobayashi Y, Kobayashi Y et al. Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002 Jun; 301(3): 797-802.; Lee SC, Zhang L, Huang SM. Regulatory science perspectives on transporter studies in drug development. In: You G, Morris ME, eds. Drug Transporters: Molecular Characterization and Role in Drug Disposition. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2014. P. 473-487.; Романов БК, Глаголев СВ, Поливанов ВА, Леонова МВ. Мониторинг безопасности лекарственных средств. Безопасность и риск фармакотерапии 2014; 3: 11-14.; Романов БК. Кальциевая регуляция активности лизосомальных ферментов миокарда. Биомедицинская химия 2005; 6 (51): 634-642.; Снегирева ИИ, Затолочина КЭ, Озерецковский НА, Романов БК, Миронов АН. Фармаконадзор вакцин в России: нормативно-правовое регулирование, особенности развития на современном этапе. Ведомости Научного центра экспертизы средств медицинского применения 2014; 4: 27-31.; Романов БК, Торопова ИИ. Неправильное применение лекарственных средств. Безопасность и риск фармакотерапии 2014; 2: 28-30.; Kreuter J, Alyautdin RN. Using nanoparticles to target drugs to the central nervous system. The blood-brain barrier and drug delivery to the CNS. New York; 2000.; Меркулов ВА, Бунятян НД, Сакаева ИВ, Рычихина ЕМ, Лепахин ВК, Романов БК, Комратов АВ, Кошечкин КА, Козлович АВ. Совершенствование системы оценки информации о безопасности лекарственных средств при проведении клинических исследований. Ведомости Научного центра экспертизы средств медицинского применения 2014; 1: 20-26.; Снегирева ИИ, Затолочина КЭ, Дармостукова МА, Аляутдин РН, Романов БК. Современные подходы к взаимозаменяемости вакцин. Ведомости Научного центра экспертизы средств медицинского применения 2016; 4: 3-8.; https://www.risksafety.ru/jour/article/view/71; undefined

الاتاحة: https://www.risksafety.ru/jour/article/view/71

المؤلفون: K. Mirzaev B., R. Kazakov E., V. Smirnov V., D. Andreev A., D. Sychev A., К. Мирзаев Б., Р. Казаков Е., В. Смирнов В., Д. Андреев А., Д. Сычев А.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 11, No 4 (2015); 344-354 ; Рациональная Фармакотерапия в Кардиологии; Vol 11, No 4 (2015); 344-354 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2015-11-4

مصطلحات موضوعية: CYP2C19*2, acute coronary syndrome, CYP3A4, pharmacogenetics, clopidogrel, P2Y12-receptor blockers, острый коронарный синдром, фармакогенетика, клопидогрел, блокаторы P2Y12-рецепторов

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/125/134; https://www.rpcardio.com/jour/article/view/125/135; Ruggeri Z.M., Platelets in atherothrombosis, Nature Med, 2002;8:1227-34.; Montalescot G, Sechtem U, Achenbach S, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34(38):2949-3003.; Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012;33(20):2569-619.; Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32(23):2999-3054.; Breet NJ, van Werkum JW, Bouman HJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010;303(8):754-762.; Elsenberg EH, van Werkum JW, van de Wal RM, et al. The influence of clinical characteristics, laboratory and inflammatory markers on ’high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009;102:719-27.; Voisin S1, Bongard V, Tidjane MA, et al. Are P2Y12 reaction unit (PRU) and % inhibition index equivalent for the expression of P2Y12 inhibition by the VerifyNow assay? Role of haematocrit and haemoglobin levels. Thromb Haemost2011;106(2):227-9.; Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.; Serebruany VL, Steinhubl SR, Berger PB, et al. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005; 45: 246-251.; Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol. 1992;44(3):527-32.; Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 2010;38:92-9; Beitelshees AL, Horenstein RB, Vesely MR, Mehra MR, Shuldiner AR. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. Clin Pharmacol Ther. 2011;89:455-9.; Lamba JK, Lin YS, Thummel K, Daly A, et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 2002;12:121-32.; Mičuda S, Šišpera L, HodačM, et al. Diurnal Variation of 6β-Hydroxycortisol in Cardiac Patients. Physiol Res 2007; 56: 307-313.; Angiolillo DJ, Bernardo E, Sabate M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50: 1541-1547.; Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849-856.; Pettersen AÅ, Seljeflot I, Abdelnoor M, et al. High on aspirin platelet reactivity and clinical outcome in patients with stable coronary artery disease: results from ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc. 2012;1:e000703; Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013;382: 614-23.; Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost. 2010;103(4):841-848.; Aradi D, Kom´ ocsi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J. 2010;160(3):543-551.; Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35(4):209-215.; Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 2010;304(16):1821-30.; Scott SA, Sangkuhl K, Stein CM et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013;94(3):317-23.; Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011;58:e44-122.; Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:645-81.; Tatarunas V, Jankauskiene L, Kupstyte N, et al. The role of clinical parameters and of CYP2C19 G681 and CYP4F2 G1347A polymorphisms on platelet reactivity during dual antiplatelet therapy. Blood Coagul Fibrinolysis 2014;25(4):369-74.; Sulimov V.A., Moroz E.V. Resistance to antiplatelet drugs (aspirin, clopidogrel) in patients undergoing elective percutaneous coronary intervention. Rational Pharmacother. Card. 2012;8(1):23-30. Russian (Сулимов В.А., Мороз Е.В. Резистентность к антитромбоцитарным препаратам (аспирину, клопидогрелу) у пациентов, подвергающихся элективному стентированию коронарных артерий. Рациональная фармакотерапия в кардиологии 2012;8(1):23-30.); Komarov A.L., Shahmatova O.O., Iljushhenko T.A., et al. Assessing Risk of Cardiovascular Events in Clopidogrel-Treated Patients with Stable CHD: Platelet Function or Genetic Testing? Doktor.Ru 2012; 6:11-; Russian (Комаров А.Л., Шахматова О.О., Илющенко Т.А., и др. Оценка риска сердечно-сосудистых осложнений у больных стабильной ИБС, получающих клопидогрел: функция тромбоцитов или генетические исследования? Доктор.Ру 2012; 6:11-19); Goluhova E.Z., Grigorjan M.V., Rjabinina M.N., et al. The platelet reactivity after percutaneous coronary intervention in patients with double antiplatelet therapy: impact of genetic polymorphisms. Kreativnaja kardiologija 2014; 3:39-52. Russian (Голухова Е.З., Григорян М.В., Рябинина М.Н., и др. Современные аспекты фармакогенетики клопидогрела и его клиническое значение. Креативная кардиология 2014; 3:39-52.); Mazurov A.V., Zjurjaev I.T., Haspekova S.G., et al. Factors influencing platelet aggregation in patients with acute coronary syndrome. Terapevticheskij arhiv 2014; 9:83-89. Russian (Мазуров А.В., Зюряев И.Т., Хаспекова С.Г., и др. Факторы, влияющие на агрегационную активность тромбоцитов у больных с острым коронарным синдромом. Терапевтический архив 2014; 9:83-89.); Hu ZY, Zhao YS, Wu D et al. Еndogenous cortisol 6 beta-hydroxylation clearance is not an accurate probe for overall cytochrome P450 3A phenotyping in humans. Clin Chim Acta 2009;408(1-2): 92-7.; https://www.rpcardio.com/jour/article/view/125

الاتاحة: https://www.rpcardio.com/jour/article/view/125
https://doi.org/10.20996/1819-6446-2015-11-4-344-354